文献速递头颈部肿瘤放疗

ARTFORCE III期试验:PET引导自适应剂量重分布放疗的急性和长期毒性及最终肿瘤学结局

Acute and long-term toxicity profiles and final oncologic outcomes in the phase III ARTFORCE trial.
PubMed 文献 · Radiother Oncol · 2026-05-10

该多中心随机III期试验在局部晚期头颈鳞癌患者中比较FDG-PET引导的自适应剂量重分布放疗(rRT)与常规放疗(cRT),两组均同步三周期100 mg/m2顺铂。试验在计划入组84%时关闭(221例可评估),急性毒性相似,5年局部区域控制与2年结果一致(HR 0.78;95%CI 0.45-1.36;P=0.39),rRT组晚期≥3级咽喉狭窄更高(0% vs 4%,P=0.05),结论支持rRT长期安全性。

要点

  • rRT与cRT的急性毒性相似(P≥0.10)。
  • 5年局部区域控制与2年结果一致(HR 0.78;95%CI 0.45-1.36;P=0.39)。
  • rRT组晚期≥3级咽喉狭窄更高(0% vs 4%,P=0.05),其余毒性无差异。

核心结论

  • FDG-PET引导的自适应剂量重分布放疗与常规放疗相比,急性和长期毒性、肿瘤控制及生存相似。
  • 这些发现证实了先前报告的2年结果,并支持rRT的长期安全性。

研究设计与样本

  • 多中心随机III期试验,纳入T3-4、N0-3、M0局部晚期头颈鳞状细胞癌患者。
  • 按1:1随机分配至rRT(64-84 Gy/35次,第10次时自适应)或cRT(70 Gy/35次),均同步三周期100 mg/m2顺铂。
  • 试验在计划入组84%时关闭,可评估221例(rRT=109,cRT=112)。

主要发现

  • 急性毒性发生率两组相似(P≥0.10)。
  • 5年局部区域控制与2年结果一致(HR 0.78;95%CI 0.45-1.36;P=0.39)。
  • 晚期毒性结果与2年结果一致,rRT组≥3级咽喉狭窄更高(0% vs 4%,P=0.05),未发现其他毒性差异。
  • 大多数毒性在2年后稳定,但甲状腺功能减退和纤维化在5年随访期间增加。
  • 探索性亚组分析显示口咽癌和N0-1疾病患者有 favoring rRT 的趋势,未发现其他可能受益于rRT的亚组。

关键数值与推荐

  • rRT剂量方案:64-84 Gy/35次,第10次时自适应。
  • cRT剂量方案:70 Gy/35次。
  • 同步化疗:三周期100 mg/m2顺铂。
  • 5年局部区域控制:HR 0.78;95%CI 0.45-1.36;P=0.39。
  • 晚期≥3级咽喉狭窄:rRT组0% vs cRT组4%,P=0.05。

临床怎么用

  • rRT可作为局部晚期头颈鳞癌的长期安全放疗策略,肿瘤控制与常规放疗相似。
  • 需关注rRT组晚期≥3级咽喉狭窄风险(0% vs 4%,P=0.05)。
  • 5年随访期间应监测甲状腺功能减退和纤维化。
  • 口咽癌和N0-1疾病患者可能从rRT中获益的趋势需进一步验证。

局限性

  • 试验在计划入组84%时关闭,可评估221例。
  • 探索性亚组分析结果仅为趋势,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We previously published the two-year outcomes of a multicenter randomized phase III trial evaluating whether FDG-PET-guided adaptive dose-redistributed radiotherapy (rRT) could improve locoregional control (LRC) in locally advanced head and neck squamous cell carcinoma (LAHNSCC) without increasing toxicity. This paper reports on acute and five-year toxicity as well as five-year oncologic outcomes. MATERIALS AND METHODS: Patients with T3-4, N0-3, M0 LAHNSCC were randomized (1:1) to rRT (64-84 Gy in 35 fractions with adaptation at fraction 10) or conventional radiotherapy (cRT; 70 Gy in 35 fractions), both with concurrent three-cycle 100 mg/m2 cisplatin. RESULTS: The trial closed at 84% of planned accrual (221 eligible; rRT = 109, cRT = 112). Acute toxicity rates were similar between arms (P ≥ 0.10). At five years, LRC remained consistent with the two-year results (HR 0.78; 95% CI 0.45-1.36; P = 0.39). Late toxicity results were also consistent with the two-year results, showing higher grade ≥ 3 pharyngolaryngeal stenosis in the rRT arm (0% vs 4%, P = 0.05). No additional differences in toxicities were found. Most toxicities stabilized after two years, but hypothyroidism and fibrosis increased throughout the five-year follow up. Exploratory subgroup analyses show trends favoring rRT in patients with oropharyngeal cancer and N0-1 disease. No additional subgroups were identified that might be benefitted by rRT. CONCLUSION: FDG-PET-guided adaptive dose-redistributed radiotherapy resulted in similar acute and long-term toxicity, tumor control and survival as cRT. These findings confirm the previously reported two-year results and support the long-term safety of rRT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. de Leeuw ALMP, Giralt J, Tao Y, et al. Acute and long-term toxicity profiles and final oncologic outcomes in the phase III ARTFORCE trial. Radiother Oncol. 2026. PMID: 42119642. doi:10.1016/j.radonc.2026.111572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。